Carlos Correa DVOA, Advanced Stats, & Fantasy Rankings

Minnesota Twins shortstop Carlos Correa (wrist) left Tuesday's 6-3 win over the New York Mets early due to left-wrist soreness, according to the team. Correa appeared to injure his wrist after taking a swing in the fifth inning. The 30-year-old went 1-for-2 with an RBI before departing. Willi Castro moved from third base to shortstop after Correa's injury, with Brooks Lee entering the contest to play third base. Correa will likely go for testing after the game, at which point we should have a better idea of the severity of his wrist injury on Tuesday night or Wednesday morning. It's certainly a concerning development for the Twins, especially since Matt Wallner (hamstring) also left this game with an injury. In addition to his injury, Correa entered Tuesday's game hitting just .153 (9-for-59) with no home runs. Lee would be in line for regular playing time if Correa is forced to the injured list.

Minnesota Twins shortstop Carlos Correa is not in the starting lineup on Sunday when the Twins conclude a series against the Detroit Tigers. Correa has started in each of the first 15 games of the regular season. As a result, utility man Willi Castro will cover shortstop in this contest and bat third. After posting an underwhelming .111/179/.139 slash line through his first 10 games of the regular season, Correa has begun to turn the corner, posting a .263/.333/.474 slash line with four doubles over his last five contests. Fantasy managers should expect the 30-year-old to return to the starting nine on Monday evening when the Twins host the New York Mets. Despite his slow start, Correa remains a must-start option in all formats as he posted a .310/.388/.517 line last summer.

Minnesota Twins shortstop Carlos Correa went 0-for-4 on Thursday afternoon against the Royals and is hitting just .149 (7-for-47) in his first 13 games this season. He began the year with an 0-for-18 stretch and is just 5-for-26 (.192) over his last seven games. Correa does have four doubles, four walks, and five runs scored in his 13 games, and his 41.0% hard-hit rate is not a drastic drop from last year's mark. He had a slow spring training as well and hasn't been able to find his rhythm yet at the plate. After the loss on Thursday, the Twins have struggled to a 4-9 start to the season, and they'll come home this weekend to host their division-rival Tigers for a three-game set.

According to Matthew Leach of MLB.com, Minnesota Twins shortstop Carlos Correa (foot) has "no issues" entering spring training. Correa missed more than two months of play last season due to plantar fasciitis. However, when on the field, the shortstop was very productive, posting a .310/.388/.517 slash line with 14 home runs. He added 58 RBI and 54 runs. Under the hood, he generated a strong .358 xwOBA and showed a great eye at the plate with a 16.6% strikeout rate and a 10.9% walk rate. Fantasy managers should continue monitoring his status during spring training in case he faces a setback. The 30-year-old should be expected to operate as the everyday shortstop in Minnesota and should be poised for a successful 2025 campaign with this injury behind him.

Minneapolis Star Tribune's Bobby Nightengale reports that the Minnesota Twins have received calls from teams interested in trading for shortstop Carlos Correa. The veteran shortstop is owed over $120 million over the next four seasons and has been limited to 221 games in the last two seasons due to various injuries, most notably with his feet. The 30-year-old Puerto Rican and three-time All-Star played in only 86 games in 2024 but swung the bat well when healthy, slashing .310/.388/.517 with a .905 OPS, 14 home runs, 54 RBI and 55 runs scored. Correa is recovering nicely in the offseason and should be ready for next year. He showed that he still has above-average power, but because of durability issues with his feet, interested teams aren't likely to offer much to Minnesota. There are also long-term concerns about his ankle, making him a pretty big risk in real life and in fantasy in 2025 and beyond.